ASH 2025: THE 67TH ANNUAL MEETING & EXPOSITION

ASH 2025: THE 67TH ANNUAL MEETING & EXPOSITION

+ Include:  videos +  pdf, size:  GB
+ Target Audience: hematologist-oncologists, pathologists
+ Information:

ASH 2025: THE 67TH ANNUAL MEETING & EXPOSITION

“Defining the Future of Blood: Gene Therapy, Immunotherapy & Beyond”

Conference Dates: December 6 – 9, 2025  Location: New Orleans, Louisiana (Ernest N. Morial Convention Center) Academic Host: American Society of Hematology (ASH)

 General Information

Welcome to the “Super Bowl” of Hematology. The ASH Annual Meeting is the global benchmark where practice-changing data is released. If it happens in blood, it happens here.

The 2025 edition in New Orleans marks a pivotal shift: we move from “experimental” gene editing to commercial reality. This course is not just about the science; it is about the logistics of cure. From the latest CAR-T constructs for solid tumors to the real-world implementation of CRISPR for Sickle Cell Disease, this curriculum defines the standard of care for the next decade.

• Format: Scientific Plenary Sessions + Education Programs + Satellite Symposia.

• Scope: Malignant Hematology (70%) / Non-Malignant & Coagulation (30%).

 Target Audience

This syllabus is the mandatory annual update for:

1. Hematologist-Oncologists: Who need to decide between Bispecific Antibodies and CAR-T therapy for their relapsed Myeloma and Lymphoma patients.

2. Pathologists: Integrating AI-driven diagnostics and next-gen sequencing (NGS) into daily reporting.

3. Transplant Physicians: Managing the toxicities of cellular therapies (CRS/ICANS) in an outpatient setting.

4. General Practitioners/Hospitalists: Who need to recognize the “red flags” of hematologic emergencies and manage the long-term survivors of gene therapy.

 Learning Objectives

By analyzing the 2025 Late-Breaking Abstracts, participants will be able to:

1. Revolutionize Myeloma Care: Apply the 2025 algorithms for Quadruplet Therapy in newly diagnosed Multiple Myeloma and sequence BCMA-targeted agents in relapse.

2. Implement Gene Editing: Navigate the referral and management pathways for Casgevy (Exa-cel) and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia.

3. Target AML Precision: Utilize Menin Inhibitors for KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

4. Manage Hemophilia: Transition patients from factor replacement to Gene Therapy (Hemgenix/Roctavian) and non-factor replacement therapies.

 Course Topics & Tracks (2025 Predictions)

The curriculum focuses on the highest-yield clinical areas.

TOPIC 1: The Myeloma & Lymphoma Revolution

• Bispecifics vs. CAR-T: The “Great Debate.” When to use “off-the-shelf” antibodies (Teclistamab, Talquetamab) versus autologous cell therapy.

• MCL & CLL: Moving towards “Chemo-Free” combinations (BTK inhibitors + BCL2 inhibitors) as first-line standards.

TOPIC 2: Leukemia & Myeloid Malignancies

• AML Updates: The rise of “Triplet” therapies (HMA + Venetoclax + Novel Agent) for the unfit patient.

• MDS Classification: Mastering the new WHO vs. ICC classifications—it’s not just “MDS” anymore; it’s molecularly defined.

TOPIC 3: Non-Malignant Hematology (Red Cell & Coag)

• Sickle Cell Cure: Real-world data on the first cohort of patients treated with CRISPR gene editing—safety, off-target effects, and fertility preservation.

• ITP & TTP: New agents targeting the complement system and FcRn inhibitors.

TOPIC 4: Immuno-Oncology & Toxicity Management

• CRS & ICANS: 2025 Protocols for managing Cytokine Release Syndrome and Neurotoxicity without admitting every patient to the ICU.

• Infection Prevention: Prophylaxis strategies for the profoundly immunosuppressed patient on B-cell maturation antigen (BCMA) therapy.